.
After market close on February 17, the company released Q4 2025 results showing revenue of $103.6 million, up 21% year-over-year and exceeding analyst expectations by over 10%. Full-year revenue reached $329.5 million, a 12% increase, with EPS of $0.46 topping the $0.44 consensus by 4.5%. Management issued 2026 revenue guidance of $357-365 million, implying 8-11% growth amid expanded lymphedema offerings. A concurrent $6.8 million acquisition of LymphaTech added.
https://finviz.com/quote.ashx?t=TCMD&p=d
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.